Application of reagent for detecting IgA immune complex

Abstract

The invention belongs to the field of immunodetection, and discloses application of a reagent for detecting an IgA immune complex. The reagent provided by the invention comprises the molecular probe, and the molecular probe comprises an Fc receptor protein of IgA and is used for being specifically combined with an IgA immune complex so as to detect the concentration of the IgA immune complex, so that a diagnostic basis is provided for IgA immune complex related diseases such as IgA nephropathy and anaphylactoid purpura, and the accuracy is high; the diagnostic product provided by the invention comprises a reagent capable of detecting the IgA immune complex, not only can diagnose whether a patient suffers from diseases related to the IgA immune complex, but also can judge the prognosis of the patient, and the diagnostic product integrates multiple diagnostic functions and has a wide clinical application prospect.

Description

technical field

[0001] The invention belongs to the field of immune detection, in particular to the application of a reagent for detecting IgA immune complexes. Background technique

[0002] In the process of human autoimmunity, when human immunoglobulin A (IgA, including 2 antigen-binding fragments (Fab) and 1 crystalline fragment (Fc)) is involved, IgA binds to pathogens to initiate an immune response, and downstream antibodies IgG and IgM , C3 complement and other molecules of the complement pathway participate in the formation of IgA-IgG, IgA-IgM, IgA-C3, IgA-IgG-IgM, etc., collectively referred to as IgA complexes. During normal immune responses, these pathogen-bound complexes are generally cleared by the immune system, such as by phagocytosis by macrophages. When the IgA immune response is abnormal, the IgA complex cannot be effectively cleared by the immune system, so that it is retained in the blood circulatory system and the urinary system for a long time, resultin...

Examples

Embodiment 1

[0057] This example provides a reagent for detecting IgA immune complexes (IgA immune activity index is characterized by detecting the concentration of IgA immune complexes, and the IgA immune activity index refers to the concentration of IgA immune complexes in serum / plasma) The kit includes a molecular probe named HQP001, and the molecular probe HQP001 is the Fc receptor protein (FCAR or CD89) of IgA.

[0058] The above kit includes: molecular probe HQP001 lyophilized powder, coating buffer, ELISA plate, standard substance, enzyme-labeled secondary antibody, chromogenic solution, stop solution, washing solution, diluent and blocking solution.

[0059] Among them, molecular probe HQP001 freeze-dried powder is recombinant FCAR protein freeze-dried powder;

[0060] The coating buffer is 0.05M carbonate buffer (pH=9.6);

[0061] 96-well plate was selected for the microplate plate;

[0062] The standard is commercial human serum IgA;

[0063] The enzyme-labeled secondary antib...

Embodiment 2

[0074] In this example, the kit proposed in Example 1 is used to detect the IgA immune activity index in the peripheral blood serum of patients diagnosed with renal puncture (IgA nephropathy), so as to verify the diagnosis result of renal puncture.

[0075] figure 2 IgA immune activity index was tested in sera from 12 children's hospital patients with IgA nephropathy (confirmed by renal biopsy), 19 healthy children and 13 healthy adults. Collect the peripheral blood of the above-mentioned three groups of people, extract serum, and then use the kit proposed in Example 1 to detect according to the detection method proposed in Example 1, and the results are as follows: figure 2 shown. figure 2 , the horizontal line between 10 and 20 is the maximum value (=16) of the IgA immune activity index of healthy people (including children and adults), which is set as the threshold line, and the IgA immune activity index is higher than the threshold line 16 is positive, below the thres...

Embodiment 3

[0077] In this example, the kit proposed in Example 1 is used to evaluate the drug effect of renal puncture in patients with IgA nephropathy.

[0078] At present, there is no complete cure for IgA nephropathy, and the main goal of treatment is disease control. The clinical manifestations of disease control are reflected in three aspects: (1) proteinuria decreases or disappears; (2) creatinine remains stable for a long time, and the normal range of serum creatinine is 44-133, including 53-106 in males and 44-97 in females; (3) ) blood pressure is normal. For patients with effective treatment, the treatment process generally takes six months to two years to control the disease, that is, the above three indicators improve and reach the normal range. However, 40% of IgA nephropathy patients eventually develop renal failure (End Stage Kidney Disease, ESKD). It can be seen that the response time of the above clinical indicators to the treatment effect lags 3-6 months.

[0079] Th...

technical field

[0001] The invention belongs to the field of immune detection, in particular to the application of a reagent for detecting IgA immune complexes. Background technique

[0002] In the process of human autoimmunity, when human immunoglobulin A (IgA, including 2 antigen-binding fragments (Fab) and 1 crystalline fragment (Fc)) is involved, IgA binds to pathogens to initiate an immune response, and downstream antibodies IgG and IgM , C3 complement and other molecules of the complement pathway participate in the formation of IgA-IgG, IgA-IgM, IgA-C3, IgA-IgG-IgM, etc., collectively referred to as IgA complexes. During normal immune responses, these pathogen-bound complexes are generally cleared by the immune system, such as by phagocytosis by macrophages. When the IgA immune response is abnormal, the IgA complex cannot be effectively cleared by the immune system, so that it is retained in the blood circulatory system and the urinary system for a long time, resultin...

Examples

Embodiment 1

[0057] This example provides a reagent for detecting IgA immune complexes (IgA immune activity index is characterized by detecting the concentration of IgA immune complexes, and the IgA immune activity index refers to the concentration of IgA immune complexes in serum / plasma) The kit includes a molecular probe named HQP001, and the molecular probe HQP001 is the Fc receptor protein (FCAR or CD89) of IgA.

[0058] The above kit includes: molecular probe HQP001 lyophilized powder, coating buffer, ELISA plate, standard substance, enzyme-labeled secondary antibody, chromogenic solution, stop solution, washing solution, diluent and blocking solution.

[0059] Among them, molecular probe HQP001 freeze-dried powder is recombinant FCAR protein freeze-dried powder;

[0060] The coating buffer is 0.05M carbonate buffer (pH=9.6);

[0061] 96-well plate was selected for the microplate plate;

[0062] The standard is commercial human serum IgA;

[0063] The enzyme-labeled secondary antib...

Embodiment 2

[0074] In this example, the kit proposed in Example 1 is used to detect the IgA immune activity index in the peripheral blood serum of patients diagnosed with renal puncture (IgA nephropathy), so as to verify the diagnosis result of renal puncture.

[0075] figure 2 IgA immune activity index was tested in sera from 12 children's hospital patients with IgA nephropathy (confirmed by renal biopsy), 19 healthy children and 13 healthy adults. Collect the peripheral blood of the above-mentioned three groups of people, extract serum, and then use the kit proposed in Example 1 to detect according to the detection method proposed in Example 1, and the results are as follows: figure 2 shown. figure 2 , the horizontal line between 10 and 20 is the maximum value (=16) of the IgA immune activity index of healthy people (including children and adults), which is set as the threshold line, and the IgA immune activity index is higher than the threshold line 16 is positive, below the thres...

Embodiment 3

[0077] In this example, the kit proposed in Example 1 is used to evaluate the drug effect of renal puncture in patients with IgA nephropathy.

[0078] At present, there is no complete cure for IgA nephropathy, and the main goal of treatment is disease control. The clinical manifestations of disease control are reflected in three aspects: (1) proteinuria decreases or disappears; (2) creatinine remains stable for a long time, and the normal range of serum creatinine is 44-133, including 53-106 in males and 44-97 in females; (3) ) blood pressure is normal. For patients with effective treatment, the treatment process generally takes six months to two years to control the disease, that is, the above three indicators improve and reach the normal range. However, 40% of IgA nephropathy patients eventually develop renal failure (End Stage Kidney Disease, ESKD). It can be seen that the response time of the above clinical indicators to the treatment effect lags 3-6 months.

[0079] Th...

Images